期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Crisis, Stimulus Package and Migration in China 被引量:2
1
作者 Maria Csanadi Zihan Nie Shi Li 《China & World Economy》 SCIE 2015年第5期43-62,共20页
This paper analyzes the short-term and long-term effects that the global economic crisis and the investment priorities of the Chinese Government's stimulus package had on Chinese migrant flows between 2008 and 2014. ... This paper analyzes the short-term and long-term effects that the global economic crisis and the investment priorities of the Chinese Government's stimulus package had on Chinese migrant flows between 2008 and 2014. Combining micro-level household survey data and macro-level statistics, the authors have found that in the short run, the regional and sectoral impact of the crisis, combined with the government's investment priorities, caused a reorientation of migration routes from the export-oriented coastal provinces towards the central and western regions, from inter-provincial migration towards intra-provincial migration, and from manufacturing industry towards the construction sector. However, in the longer run, the decreasing attractiveness of the eastern region and the increasing attractiveness of the western region proved to be transitory, although the pre-crisis relative advantage of the eastern region was not fuUy restored. What proved to be persistent were the attractiveness of the central region and the intra-provincial migration in all three regions, and, in particular, the steady growth of migrants in the construction sector. 展开更多
关键词 EMPLOYMENT MIGRATION spatial disparities stimulus package
原文传递
Moving towards the chemo-free treatment of lymphoma:hype or reality?
2
作者 Bruce D.Cheson 《Journal of Cancer Metastasis and Treatment》 2022年第1期631-636,共6页
A new generation of novel,effective targeted drugs and cellular therapies include monoclonal antibodies directed at the cell surface,such as the anti-CD-19 tafasitamab which,combined with lenalidomide,is the first the... A new generation of novel,effective targeted drugs and cellular therapies include monoclonal antibodies directed at the cell surface,such as the anti-CD-19 tafasitamab which,combined with lenalidomide,is the first therapy approved by the Food and Drug Administration for second-line treatment of diffuse large B-cell lymphoma.Other agents interfere with pro-survival intracellular signaling pathways including drugs that inhibit Bruton tyrosine kinase,phosphatidylinositol-3 kinase(PI3-kinase),and bcl-2.An increasing number of therapies impact the microenvironment,notably checkpoint inhibitors and bispecific antibodies.Chimeric antigen receptor-T cell therapy has improved the outcome of patients with a variety of histologies of lymphoma.Whereas in the past,such therapies would be used inrelapsed and refractory settings,they are now being evaluated as initial treatment in selected patients.With an improved ability to individualize treatment approaches,chemo-free will be a reality for lymphoma patients. 展开更多
关键词 LYMPHOMA targeted therapies chemo-free bispecifics BTK inhibitors PI3k inhibitors CAR-T cell
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部